SBTX Silverback Therapeutics

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its third quarter 2025 financial results and business highlights.

Dial-in information for conference participants may be obtained by . To access the webcast and slides, please visit the page in the Investors & Media section of the Company’s . A replay of the webcast will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients 4 years of age and older who weigh 15 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit .

Investor Contact:

Justin Chakma

ARS Pharmaceuticals

Monique Allaire

THRUST

Media Contact:

Christy Curran

Sam Brown Inc.

615.414.8668



EN
03/11/2025

Underlying

SBTXSilverback Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silverback Therapeutics

 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic...

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients who may already have an auto-injector, but are looking for a smaller, easier to administer option SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients a...

November 4, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephr...

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral presentation to report results from real world data on the effectiveness of epinephrine nasal spray in clinical practice Case reports to detail real-world data and effective use of neffy in patients who experience anaphylaxis during oral food challenges or allergy immunot...

November 3, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Thir...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its third quarter 2025 financial results and business highlights. Dial-in information for c...

November 3, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 202...

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral presentation reports about 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Case reports detail real-world data and effective use of neffy in patients who experience anaphylaxis during oral food challenges or allergy immunothe...

November 3, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Receives Favorable Decision from European Patent O...

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the Opposition Division of the European Patent Office (the “EPO”) upheld the validity of all claims in EP 3678649, which is a patent validated in over 30 European countries...

October 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch